Conclusion
Hypertension is the most common primary diagnosis in America. Although control rates have improved they are still far below the optimal goal. Recent clinical trials have demonstrated that effective blood pressure control can be achieved in most patients who are hypertensive, but the majority will require two or more antihypertensive drugs. Of paramount importance, clinicians should prescribe lifestyle modifications, adequate antihypertensive drug doses, or appropriate drug combinations for effective BP control. JNC 7 sets evidence based guidelines for recommendations of diagnosis and treatment of hypertension but it does not substitute for physicians' clinical decision making. A summary of the JNC 7 guidelines and this module can be found on the Physician's JNC 7 Reference Card.
Thank you for completing our module on Hypertension. Please use the link below to complete the mandatory feedback section and content questions. Your evaluation is greatly appreciated and will help us craft a more valuable learning experience. Thank you in advance for your time.
Web Resources
Bibliography
-
Arnlov et al. Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study
Circulation 2005;112:969-975. -
Betancourt JR, Carrillo JE, Green AR. Hypertension in multicultural and minority populations: Linking communication to compliance. Curr Hypertens Rep 1999;1:482-8.
-
Black HR. The evolution of low-dose diuretic therapy: the lessons from clinical trials. Am J Med 1996;101:47S-52S.
-
Boulware LE, Daumit GL, Frick KD, Minkovitz CS, Lawrence RS, Powe NR. An evidence-based review of patient-centered behavioral interventions for hypertension. Am J Prev Med. 2001 Oct;21(3):221-32. PMID: 11567845
-
Carrillo JE, MD, MPH; Green AR, MD; and Betancourt JR, MD, MPH, “Cross Cultural Primary Care: A Patient-Based Appoach.” Ann Intern Med. 1999; 103:829-834
-
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289:2560-72.
-
Collela C, Laver J. Setting the stage for changing health behavior. Nurse Pract. 2005 Oct;30(10):68-70. Review.
-
Crespo CJ, Loria CM, Burt VL. Hypertension and other cardiovascular disease risk factors
among Mexican Americans, Cuban Americans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey. Public Health Rep 1996;111:7-10. -
Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 2002;4:393-404.
-
Dickerson LM. Gibson MV. Management of hypertension in older persons. American Family Physician. 71(3):469-76, 2005 Feb 1. UI: 15712622
-
Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163:525-541.
-
Flack JM, Cushman WC. Evidence for the efficacyof low-dose diuretic monotherapy. Am J Med 1996;101:53S-60S.
-
Gardin KM, Lauer MS. Left ventricular hypertrophy: the next treatable, silent killer? JAMA. 2004 Nov 17;292(19):2396-8. No abstract available. PMID: 15547168
-
Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood
pressure? A meta-analysis. Ann Intern Med 1994;121:289-300. -
Kaplan NM. Treatment of hypertension: insights from the JNC-VI report. Am Fam Physician. 1998 Oct 15;58(6):1323-30. Review.
-
Kasper D, Braunwald, E, et al, (Editors) “Hypertensive Vascular Disease” in Harrison’s Principles of Internal Medicine. McGraw-Hill Companies; 2005. Chapter 230
-
Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
-
Lizka et al. Prehypertension and Cardiovascular Morbidity Ann Fam Med 2005;3:294-299.
-
MMWR Report, Racial/Ethnic Disparities in Prevalence, Treatment, and Control of Hypertension--United States, 1999-2002 JAMA 2005;293:923-925.
-
Mosca and for the Expert Panel/WritingGroup. Summary of the American Heart Association's Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women Arterioscler Thromb Vasc Biol 2004;24:394-396.
-
National Heart, Lung, and Blood Institute. Strong Heart Study Data Book: A Report to
American Indians Communities. Bethesda, MD: National Institutes of Health, National Heart,
Lung, and Blood Institute. NIH Publication No. 01-3285, 2001. -
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents Pediatrics 2004; 114: 555-576
-
O’ Connor. Overcome Clinical Inertia to Control Systolic Blood Pressure Arch Intern Med 2003;163:2677-2678.
-
Oparil et al. Pathogenesis of Hypertension Ann Intern Med 2003;139:761-776.
-
Parsons DS, Reaveley DA, Pavitt DV, Brown EA. Relationship of renal function to homocysteine and lipoprotein(a) levels: The frequency of the combination of both risk factors in chronic renal impairment. Am J Kidney Dis 2002;40:916-23.
-
Radermacher J. Haller H. The right diagnostic work-up: investigating renal and renovascular disorders. Journal of Hypertension - Supplement. 21 Suppl 2:S19-24, 2003 May. UI: 12929903
-
Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and lowdensity lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
-
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
-
Sowers JR, Haffner S. Treatment of cardiovascular and renal risk factors in the diabetic hypertensive. Hypertension 2002;40:781-8.
-
U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Facts about the DASH eating plan. Available at:
http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/index.htm. Accessed November, 2003. -
Varon J, Marik PE. Clinical review: the management of hypertensive crises.
Crit Care. 2003 Oct;7(5):374-84. Epub 2003 Jul 16. Review. -
Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, et al. Impact of high normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.
Westphal SA. Diagnosis of a pheochromocytoma. American Journal of the Medical Sciences. 329(1):18-21, 2005 Jan. UI: 15654175
-
Wooten, J., et. al., Polypharmacy: Keeping the elderly safe. RN v. 68 no. 8 (August 2005) p. 44-51
-
Young WF Jr. Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. Endocrinology. 144(6):2208-13, 2003 Jun. UI: 12746276